Antibody data
- Antibody Data
- Antigen structure
- References [21]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [14]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 13-9948-80 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD278 (ICOS) Monoclonal Antibody (ISA-3), Biotin, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The ISA-3 monoclonal antibody reacts with human ICOS (Inducible COStimulatory molecule), also known as H4, CRP-1 and AILIM. ICOS is a T cell specific activation molecule and a third member of the CD28/CTLA-4 family. Human ICOS has a relative molecular mass of 55-60 kDa, composed of 27 kDa and 29 kDa chains. Human ICOS on activated T cells has potent costimulatory activity for T cell activation and is required for humoral immune responses, in particular for memory B cell and plasma cell generation. ICOS binds to its ligand, B7h/B7RP-1 expressed on activated APCs (antigen presenting cells) and on a number of inflamed peripheral tissues. Plate-bound ISA-3 is costimulatory for T cells and induces production of IL-4, IL-5, IL-10 and other cytokines, but not IL-2. ISA-3 has the same reactivity pattern and characteristics as F44. ISA-3 was generated against the human ICOS antigen. C398.4A, anti-mouse ICOS/H4 (cat. 14-9949-82), was shown to cross-react with human ICOS but binds to an epitope different from ISA-3. C398.4A stains activated cells brighter than ISA-3; however, it also exhibits higher staining of non-activated human peripheral blood or isolated PBMC. To achieve the brightest staining of ICOS on activated human T cells, please use 13-9948-82 or 12-9948-42 rather than 11-9948-42.
- Conjugate
- Biotin
- Antibody clone number
- ISA-3
- Concentration
- 0.5 mg/mL
Submitted references Inducible Costimulator-C-X-C Motif Chemokine Receptor 3 Signaling is Involved in Chronic Obstructive Pulmonary Disease Pathogenesis.
Impaired HA-specific T follicular helper cell and antibody responses to influenza vaccination are linked to inflammation in humans.
Protein/AS01(B) vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors.
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.
IL-21-Deficient T Follicular Helper Cells Support B Cell Responses Through IL-27 in Patients With Chronic Hepatitis B.
The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRβ clonotypes.
Distribution of circulating follicular helper T cells and expression of interleukin-21 and chemokine C-X-C ligand 13 in gastric cancer.
Roquin targets mRNAs in a 3'-UTR-specific manner by different modes of regulation.
Dysregulated ICOS(+) proinflammatory and suppressive regulatory T cells in patients with rheumatoid arthritis.
CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer.
Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS.
CD28 family of receptors on T cells in chronic HBV infection: Expression characteristics, clinical significance and correlations with PD-1 blockade.
Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors.
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.
Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers.
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells.
Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells.
Inducible costimulator: a modulator of IFN-gamma production in human tuberculosis.
Inducible costimulator: a modulator of IFN-gamma production in human tuberculosis.
Li DY, Chen L, Miao SY, Zhou M, Wu JH, Sun SW, Liu LL, Qi C, Xiong XZ
International journal of chronic obstructive pulmonary disease 2022;17:1847-1861
International journal of chronic obstructive pulmonary disease 2022;17:1847-1861
Impaired HA-specific T follicular helper cell and antibody responses to influenza vaccination are linked to inflammation in humans.
Hill DL, Whyte CE, Innocentin S, Lee JL, Dooley J, Wang J, James EA, Lee JC, Kwok WW, Zand MS, Liston A, Carr EJ, Linterman MA
eLife 2021 Nov 2;10
eLife 2021 Nov 2;10
Protein/AS01(B) vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors.
Nielsen CM, Ogbe A, Pedroza-Pacheco I, Doeleman SE, Chen Y, Silk SE, Barrett JR, Elias SC, Miura K, Diouf A, Bardelli M, Dabbs RA, Barfod L, Long CA, Haynes BF, Payne RO, Minassian AM, Bradley T, Draper SJ, Borrow P
Cell reports. Medicine 2021 Mar 16;2(3):100207
Cell reports. Medicine 2021 Mar 16;2(3):100207
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.
Minassian AM, Silk SE, Barrett JR, Nielsen CM, Miura K, Diouf A, Loos C, Fallon JK, Michell AR, White MT, Edwards NJ, Poulton ID, Mitton CH, Payne RO, Marks M, Maxwell-Scott H, Querol-Rubiera A, Bisnauthsing K, Batra R, Ogrina T, Brendish NJ, Themistocleous Y, Rawlinson TA, Ellis KJ, Quinkert D, Baker M, Lopez Ramon R, Ramos Lopez F, Barfod L, Folegatti PM, Silman D, Datoo M, Taylor IJ, Jin J, Pulido D, Douglas AD, de Jongh WA, Smith R, Berrie E, Noe AR, Diggs CL, Soisson LA, Ashfield R, Faust SN, Goodman AL, Lawrie AM, Nugent FL, Alter G, Long CA, Draper SJ
Med (New York, N.Y.) 2021 Jun 11;2(6):701-719.e19
Med (New York, N.Y.) 2021 Jun 11;2(6):701-719.e19
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.
Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, Takehara KK, Eggenberger J, Hemann EA, Waterman HR, Fahning ML, Chen Y, Hale M, Rathe J, Stokes C, Wrenn S, Fiala B, Carter L, Hamerman JA, King NP, Gale M Jr, Campbell DJ, Rawlings DJ, Pepper M
Cell 2021 Jan 7;184(1):169-183.e17
Cell 2021 Jan 7;184(1):169-183.e17
IL-21-Deficient T Follicular Helper Cells Support B Cell Responses Through IL-27 in Patients With Chronic Hepatitis B.
Khanam A, Ayithan N, Tang L, Poonia B, Kottilil S
Frontiers in immunology 2020;11:599648
Frontiers in immunology 2020;11:599648
The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRβ clonotypes.
Hill DL, Pierson W, Bolland DJ, Mkindi C, Carr EJ, Wang J, Houard S, Wingett SW, Audran R, Wallin EF, Jongo SA, Kamaka K, Zand M, Spertini F, Daubenberger C, Corcoran AE, Linterman MA
The Journal of experimental medicine 2019 Aug 5;216(8):1857-1873
The Journal of experimental medicine 2019 Aug 5;216(8):1857-1873
Distribution of circulating follicular helper T cells and expression of interleukin-21 and chemokine C-X-C ligand 13 in gastric cancer.
Meng X, Yu X, Dong Q, Xu X, Li J, Xu Q, Ma J, Zhou C
Oncology letters 2018 Sep;16(3):3917-3922
Oncology letters 2018 Sep;16(3):3917-3922
Roquin targets mRNAs in a 3'-UTR-specific manner by different modes of regulation.
Essig K, Kronbeck N, Guimaraes JC, Lohs C, Schlundt A, Hoffmann A, Behrens G, Brenner S, Kowalska J, Lopez-Rodriguez C, Jemielity J, Holtmann H, Reiche K, Hackermüller J, Sattler M, Zavolan M, Heissmeyer V
Nature communications 2018 Sep 19;9(1):3810
Nature communications 2018 Sep 19;9(1):3810
Dysregulated ICOS(+) proinflammatory and suppressive regulatory T cells in patients with rheumatoid arthritis.
Wang HX, Kang X, Chu S, Li H, Li X, Yin X, Qiu YR, Lai W
Experimental and therapeutic medicine 2018 Oct;16(4):3728-3734
Experimental and therapeutic medicine 2018 Oct;16(4):3728-3734
CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer.
Gu-Trantien C, Migliori E, Buisseret L, de Wind A, Brohée S, Garaud S, Noël G, Dang Chi VL, Lodewyckx JN, Naveaux C, Duvillier H, Goriely S, Larsimont D, Willard-Gallo K
JCI insight 2017 Jun 2;2(11)
JCI insight 2017 Jun 2;2(11)
Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS.
Franzese O, Palermo B, Di Donna C, Sperduti I, Ferraresi V, Stabile H, Gismondi A, Santoni A, Nisticò P
Oncoimmunology 2016 May;5(5):e1114203
Oncoimmunology 2016 May;5(5):e1114203
CD28 family of receptors on T cells in chronic HBV infection: Expression characteristics, clinical significance and correlations with PD-1 blockade.
Tang ZS, Hao YH, Zhang EJ, Xu CL, Zhou Y, Zheng X, Yang DL
Molecular medicine reports 2016 Aug;14(2):1107-16
Molecular medicine reports 2016 Aug;14(2):1107-16
Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors.
Pedroza-Gonzalez A, Zhou G, Vargas-Mendez E, Boor PP, Mancham S, Verhoef C, Polak WG, Grünhagen D, Pan Q, Janssen H, Garcia-Romo GS, Biermann K, Tjwa ET, IJzermans JN, Kwekkeboom J, Sprengers D
Oncoimmunology 2015 Jun;4(6):e1008355
Oncoimmunology 2015 Jun;4(6):e1008355
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.
Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O
Oncoimmunology 2013 Jan 1;2(1):e23033
Oncoimmunology 2013 Jan 1;2(1):e23033
Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers.
Bentebibel SE, Schmitt N, Banchereau J, Ueno H
Proceedings of the National Academy of Sciences of the United States of America 2011 Aug 16;108(33):E488-97
Proceedings of the National Academy of Sciences of the United States of America 2011 Aug 16;108(33):E488-97
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 May 15;16(10):2861-71
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 May 15;16(10):2861-71
Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells.
Nagata S, Ise T, Pastan I
Journal of immunology (Baltimore, Md. : 1950) 2009 Jun 15;182(12):7518-26
Journal of immunology (Baltimore, Md. : 1950) 2009 Jun 15;182(12):7518-26
Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells.
Geiger R, Duhen T, Lanzavecchia A, Sallusto F
The Journal of experimental medicine 2009 Jul 6;206(7):1525-34
The Journal of experimental medicine 2009 Jul 6;206(7):1525-34
Inducible costimulator: a modulator of IFN-gamma production in human tuberculosis.
Quiroga MF, Pasquinelli V, Martínez GJ, Jurado JO, Zorrilla LC, Musella RM, Abbate E, Sieling PA, García VE
Journal of immunology (Baltimore, Md. : 1950) 2006 May 15;176(10):5965-74
Journal of immunology (Baltimore, Md. : 1950) 2006 May 15;176(10):5965-74
Inducible costimulator: a modulator of IFN-gamma production in human tuberculosis.
Quiroga MF, Pasquinelli V, Martínez GJ, Jurado JO, Zorrilla LC, Musella RM, Abbate E, Sieling PA, García VE
Journal of immunology (Baltimore, Md. : 1950) 2006 May 15;176(10):5965-74
Journal of immunology (Baltimore, Md. : 1950) 2006 May 15;176(10):5965-74
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of 2-day unstimulated (left) and 2-day Anti-Human CD3/CD28 (Product # 16-0039-81) and (Product # 16-0289-81) activated (right) PBMC with Mouse IgG1 K Isotype Control Biotin (Product # 13-4714-85) (open histogram) or Anti-Human CD278 (ICOS) Biotin (filled histogram) followed by Streptavidin PE (Product # 12-4317-87). Viable cells were analyzed.
- Conjugate
- Biotin
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 SARS-CoV-2 Infection Induces Durable, Functional Spike-Reactive CD4 + T Cells (A) Representative flow cytometry plots of ICOS and CD40L expression on antigen-experienced (non-CD45RA + CCR7 + ) CD4 + T cells 20 h after incubation of PBMCs from HC and CoV2 + individuals at V1 and V2 with vehicle or SARS-CoV-2 spike. (B) Number of antigen-experienced ICOS + CD40L + CD4 + T cells per 1x10 6 CD4 + T cells from HC and CoV2 + samples after incubation with vehicle (Veh.) or spike (S) at both time points (right) and calculated number of spike-responsive CD4 + T cells (number after incubation with spike minus number after incubation with vehicle) compared across time points (left). (C) Number of antigen-experienced CXCR5 + ICOS + CD40L + CD4 + T cells (cTfh) per 1 x 10 6 CD4 + T cells from HC and CoV2 + samples after incubation with Veh. or S at both time points (right) and calculated number of spike-responsive cTfh cells (number after incubation with spike minus number after incubation with vehicle) compared across time points (left). (D) Representative flow cytometry plots of sorted CD4 + naive (CD45RA + CCR7 + ), T CM (CD45RA - CCR7 + ), or T EM (CD45RA - CCR7 - ) T cells from HC and CoV2 + PBMCs after 5-6 days of co-culture with SARS-CoV-2 spike-protein-pulsed autologous monocytes and measuring proliferation by CPD dilution. (E) SARS-CoV-2 spike-specific expansion of sorted CD4 + naive T, T CM , and T EM cells from V1 (circles) and V2 (squares) reported as frequency of CXC
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 T FH cell compartment was altered during chronic HBV infection. (A, B) Representative flow cytometry plot indicates the percent frequencies of circulating T FH cells, PD-1 as well as ICOS expression in HC-vacc (n = 21) and CHB patients (n = 32) respectively. Throughout the flow cytometry plots, gates were placed based on single-color controls. (C, D) T FH cell subtypes were analyzed on the basis of expression of different cell surface molecules. Values in the quadrant designate the percent frequency of different T FH cell subsets. Cumulative data has been shown in scatter plot (HC-vacc: n = 21 and CHB: n = 32) and expressed as median. Each symbol on scatter plot represents an individual subject. Statistical analysis was performed using non-parametric, two-tailed Mann-Whitney U test. (E) Frequency of T FH cells in HBV patients with different ALT and HBV DNA levels, HBeAg-negative and positive patients was analyzed. Levels of ALT were divided as normal (range, 22-40; n=21) vs. raised (range, 41-193; n=15)). HBV DNA levels were divided as 10 4 (n = 8). Unpaired t-test was used for statistical significance.
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1. Robust haemagglutinin (HA)-specific CD4 + T cells' response to seasonal influenza vaccination. ( A ) Overview of cohort characteristics, vaccination strains, and immune variables measured before (d0), 7 days (d7), and 42 days (d42) after seasonal influenza vaccination. ( B ) IgG responses to HA proteins from vaccine influenza strains measured by Luminex. Dashed line indicates limit of detection in Luminex assay. ( C ) Log 2 fold change versus -log10 false discovery rate (FDR)-adjusted p-value of Flu HA Luminex, Cytokine Luminex, B cell and CD4 + T cell immunophenotyping parameters before and after vaccination at indicated time points for cohort 1. Dashed line represents the p-value cut-off at FDR-adjusted p=0.05. ( D ) Representative flow cytometry plots of HA 257-276 HLADR*0701 staining on CD4 + CD45RA - cells, gate corresponds to HA-specific TET + T cells, and ( E ) the frequency of HA-specific TET + T cells among all CD4 + CD45RA - cells on d0 compared to d7. ( F ) Representative ICOS staining and ( G ) the percentage of ICOS + cells among HA-specific TET + T cells on d0 and d7. ( H ) CXCR5 and PD1 staining on HA-specific TET + T cells on d0 and d7, gate corresponds to 'TET + cTfh' T cells, and ( I ) the percentage of circulating T follicular helper (cTfh) cells among HA-specific TET + T cells on d0 and d7 for each cohort. In parts ( D-I ), cohort 1 n = 16; cohort 2 n = 19. Paired p-values determined using Wilcoxon signed-rank test. Figure 1--figure supplement 1.
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Inducible costimulator (ICOS) signaling induces C-X-C motif chemokine receptor 3 (CXCR3) expression in vivo and in vitro. ( A ) Representative flow cytometric dot plots of the frequencies of CXCR3 + CD4 + T cells and CXCR3 + CD4 + CD25 + FOXP3 + Tregs within patients with stable chronic obstructive pulmonary disease (SCOPD). Comparisons of the percentage of CXCR3 + T cells within CD4 + T cells ( B ) and CD4 + CD25 + FOXP3 + Tregs ( C ) in the peripheral blood from 15 healthy controls (HC), 11 healthy smokers (HS), 22 patients with SCOPD (SCOPD), and 14 patients with acute exacerbation of COPD (AECOPD). ( D ) Representative gating of CXCR3 + ICOS + CD4 + T cells and CXCR3 + ICOS - CD4 + T cells and the corresponding histograms (n = 22). ( E ) Naive CD4 + T cells obtained from the peripheral blood of healthy people were cultured with plate-bound anti-CD3/28 mAbs in the presence of IL-2 with or without anti-ICOS mAb (ISA-3) for four days. The frequency of CXCR3 + CD4 + T cells was analyzed with flow cytometry. Comparable results were obtained from six independent experiments. ( F ) The percentage of CXCR3 + CD4 + T cells in the peripheral blood and corresponding BALF of four patients with SCOPD. *p
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3. A GLA-SE adjuvanted vaccine promotes cTfh expansion. (A and B) Flow cytometric contour plots of (A) PD-1 and CXCR5 on total CD45RA - CD4 + CD3 + cells and (B) ICOS and CD38 on the population gated in A on peripheral blood cells from individuals 7 d after the third P27A vaccination. Alum group, n = 7; GLA-SE group, n = 8. (C) Fold change of CD38 + ICOS + CXCR5 + PD-1 + cTfh cells 7 d after the third P27A vaccination (frequency of cTfh cells at day 63/baseline). Alum group, n = 7; GLA-SE, group n = 8. P = 0.027. The P value is from an unpaired Student's t test. (D) Correlation of anti-P27A IgG antibody titer 28 d after the third vaccination against fold change in CD38 + ICOS + CXCR5 + PD-1 + cTfh cells 7 d after the third vaccination. Rho = 0.73; P = 0.003 by Spearman's correlation (Rho = coefficient); n = 15. (E) Scatterplot of RNA-sequencing data comparing all genes expressed in CD38 + ICOS + CXCR5 + PD-1 + cTfh cells 7 d after the third P27A vaccination in either Alum- (x axis) or GLA-SE- (y axis) vaccinated groups. Alum group, n = 7; GLA-SE group, n = 8. (F-I) Bar plots showing log-normalized reads from RNA-sequencing data of CD40LG . P = 0.593 (F), IL21 P = 0.846 (G), CXCR3 P = 0.606 (H), and CCR6 P = 0.977 (I) for transcripts in ICOS in CD38 + ICOS + CXCR5 + PD-1 + cTfh cells 7 d after the third P27A vaccination; Alum group, n = 7; GLA-SE group, n = 8. P values were calculated using DESeq2 with a false discovery rate corr
- Conjugate
- Biotin